Shortwave Life Sciences (AQSE:PSY) Accounts Payable & Accrued Expense : £0.00 Mil (As of . 20)

View and export this data going back to 2022. Start your Free Trial

What is Shortwave Life Sciences Accounts Payable & Accrued Expense?

Shortwave Life Sciences Accounts Payable & Accrued Expense Historical Data

The historical data trend for Shortwave Life Sciences's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shortwave Life Sciences Accounts Payable & Accrued Expense Chart

Shortwave Life Sciences Annual Data

Trend

Accounts Payable & Accrued Expense

Shortwave Life Sciences Semi-Annual Data

Accounts Payable & Accrued Expense

Shortwave Life Sciences Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Shortwave Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shortwave Life Sciences PLC (AQSE:PSY) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.shortwavelifesciences.com

Shortwave Life Sciences PLC is a biopharmaceutical company focused in advancing pioneering therapies in mental health care, also it is involved in developing novel drug combinations and delivery methods to treat patients suffering from mental health disorders. It identifies, operates and creates value from early-stage, breakthrough initiatives, with an initial focus on eating disorders.